Share:
ResearchAndMarkets.com s offering.
Major players in the anti-asthmatics and chronic obstructive pulmonary disease (COPD) market are Novartis AG, Merck & Co, GlaxoSmithKline, Boehringer Ingelheim Gmbh and AstraZeneca.
The global anti-asthmatics and copd drugs market is expected to decline from $75.38 billion in 2020 to $66.81 billion in 2021 at a compound annual growth rate (CAGR) of -11.4%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The market is expected to reach $86.44 billion in 2025 at a CAGR of 6.7%.
The anti-asthmatics and chronic obstructive pulmonary disease (COPD) market consists of sales of anti-asthmatics and chronic obstructive pulmonary disease (COPD) drugs which are used to relieve the frequency of acute attacks of asthma, emphysema, chronic bronchitis, and nocturnal awakenings. The class of drugs includes Bronchodilators, anti-
Abuse Deterrent Formulation Technologies Market Research Report, Growth Trends and Competitive Analysis 2021-2027
Abuse Deterrent Formulation Technologies Market Size 2021 by Product Sales, Revenue, Price, Market Share, Growth Opportunity and Forecast to 2024 Research Report I Top key players- Acura Pharmaceuticals, Altus Formulation, BioDelivery Sciences International, Teva Pharmaceutical, Elysium Therapeutics, Grünenthal, Intellipharmaceutics, Purdue Pharma, TITAN Pharmaceutical
infinityMay 16, 2021
A new analytical data on the global Abuse Deterrent Formulation Technologies Market has newly been added by Infinity Business Insights to its humongous database to make strategic decisions in global businesses. The global Abuse Deterrent Formulation Technologies Market aims to offer deep insights into global businesses through this global informative report.
Action collective contre des géants pharmaceutiques droit-inc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from droit-inc.com Daily Mail and Mail on Sunday newspapers.